Xilio Therapeutics, Inc. (XLO) Misses Q1 EPS by 37c

Xilio Therapeutics, Inc. (NASDAQ: XLO) reported Q1 EPS of ($0.18), $0.37 worse than the analyst estimate of $0.19.

For earnings history and earnings-related data on Xilio Therapeutics, Inc. (XLO) click here.

You May Also Be Interested In

• Mizuho Upgrades Five Below (FIVE) to Outperform, 'we believe the pendulum has swung too far on valuation'
• PriceSmart (PSMT) Misses Q3 EPS by 4c, Beats on Revenue
• Wolfe Research Upgrades Grainger (GWW) to Peerperform (correction)